Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Pharma company Gilead Sciences has been awarded a massive $31.8 million in damages in connection with a lawsuit claiming ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...

J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.34 which represents a slight increase of $1.75 or 1.93% from the prior close of $90.59. The stock opened at $91.35 and ...

For years, Gilead Sciences was dead money for shareholders. That is starting to change, and a recent rally in the stock can ...

Gilead Sciences (NASDAQ:GILD) shares continued gains for the eighth straight session, as the stock was up 1.5% on Monday. The ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.13 which represents a decrease of $-1.26 or -1.35% from the prior close of $93.39. The stock opened at $93.5 and touched a low ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc.

The Zacks Daily presents the best research output of our analyst team. Today's Daily features new research reports on 16 ...